Squamous cell carcinomas of the skin responsive to erlotinib: 5 cases William L. Read, MD, Kevin T. Brumund, MD, FACS, Robert A. Weisman, MD, FACS, Angel Q. Nguyen, BA JAAD Case Reports Volume 1, Issue 3, Pages 153-156 (May 2015) DOI: 10.1016/j.jdcr.2015.02.014 Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Case 2. Submental recurrence of SCCS before (5/30/2006) and after (6/22/2006) erlotinib. JAAD Case Reports 2015 1, 153-156DOI: (10.1016/j.jdcr.2015.02.014) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 Case 2. Diffuse postoperative recurrence of SCCS before (1/30/207) and after (3/27/2007) erlotinib. JAAD Case Reports 2015 1, 153-156DOI: (10.1016/j.jdcr.2015.02.014) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions
Fig 3 Case 3. Diffuse regional recurrence of SCCS before (6/15/2010) and after (10/12/10) erlotinib. JAAD Case Reports 2015 1, 153-156DOI: (10.1016/j.jdcr.2015.02.014) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions
Fig 4 Case 5. New primary SCCS of skin of lip before (5/20/2007) and after (6/1/2007) erlotinib. JAAD Case Reports 2015 1, 153-156DOI: (10.1016/j.jdcr.2015.02.014) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions